Comparative Pharmacology
Head-to-head clinical analysis: EMTRIVA versus STAVUDINE LAMIVUDINE NEVIRAPINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRIVA versus STAVUDINE LAMIVUDINE NEVIRAPINE.
EMTRIVA vs STAVUDINE; LAMIVUDINE; NEVIRAPINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; emtricitabine is phosphorylated to emtricitabine 5'-triphosphate which competes with deoxycytidine 5'-triphosphate for incorporation into viral DNA, resulting in chain termination.
Stavudine is a nucleoside analog reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase. Lamivudine is an NRTI that inhibits HIV reverse transcriptase. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to HIV reverse transcriptase, causing enzyme inhibition.
Emtricitabine 200 mg orally once daily.
One tablet (stavudine 30 mg + lamivudine 150 mg + nevirapine 200 mg) orally twice daily. For patients weighing ≥60 kg, stavudine 40 mg may be used; however, due to toxicity, 30 mg is preferred. Nevirapine requires a 14-day lead-in dose of 200 mg once daily.
None Documented
None Documented
Terminal elimination half-life ~10 hours (mean 10 h, range 7-14 h) in adults; prolonged in renal impairment (up to 90 h in severe impairment)
Stavudine: 1.0-1.6 hours (mean ~1.5 h) in adults with normal renal function; prolonged in renal impairment. Lamivudine: 5-7 hours in adults; prolonged in renal impairment. Nevirapine: 25-30 hours (single dose); 40-45 hours with multiple dosing due to autoinduction.
Renal excretion of unchanged drug (~86%) by glomerular filtration and active tubular secretion; fecal excretion (<1%)
Stavudine: Renal (approximately 60% unchanged) and hepatic metabolism. Lamivudine: Renal (approximately 70% unchanged) via glomerular filtration and active tubular secretion. Nevirapine: Hepatic metabolism (CYP3A4, CYP2B6) followed by renal excretion of metabolites (about 80% in urine, 10% in feces).
Category C
Category A/B
Antiretroviral, NRTI
NRTI